Objective To report on the value of magnetic resonance imaging (MRI) and 2-deoxy-2- fluoro-D-glucose positron emission tomography computed tomography (18FDG PET-CT) in predicting resectability and pathological response of primary locally advanced cervical cancer after neoadjuvant intensity-modulated arc therapy (IMAT) with or without cisplatin (C).
Methods and Materials Twenty-seven patients with International Federation of Gynecology and Obstetrics stages IB2 to IVA cervical cancer were treated with IMAT-C followed by extrafascial hysterectomy (EH). All patients received MRI and 18FDG PET-CT after IMAT-C. The end points of this study were to:
Assess the ability of MRI to predict negative surgical margins (R0).
Assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MRI in predicting the following situation at the EH specimen: “no residual disease or minimal microscopically visible residual tumor.”
Assess the sensitivity, specificity, PPV, and NPV value of 18FDG PET-CT in predicting “no residual viable tumor cells” at the EH specimen.
Results An R0 resection was obtained in all patients. None of the EH specimens contained macroscopically visible tumor. In 13 patients, no viable tumor cells were found and only 14 had residual microscopic disease. Twenty-four of 27 MRIs were able to correctly predict R0 resection. A negative MRI was 100% predictive for the end point “R0 resection.” The specificity and NPV of MRI (end point 2) were 74% and 100%, respectively. No sensitivity or PPV could be calculated. The sensitivity, specificity, PPV, and NPV of 18FDG PET-CT were 29%, 62%, 44%, and 44%, respectively (end point 3).
Conclusions A negative MRI after IMAT-C predicts 100% correctly for R0 resection. The role of 18FDG PET-CT in predicting viable tumor cells at EH specimen is at least debatable.
- Locally advanced cervical cancer
- 18FDG PET-CT
- Tumor response
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Note: The first 2 authors contributed equally to this manuscript.
The authors have no conflict of interest.